NSEI:GLENMARK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. More Details


Snowflake Analysis

Excellent balance sheet with solid track record and pays a dividend.


Similar Companies

Share Price & News

How has Glenmark Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GLENMARK has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0.6%

GLENMARK

-1.7%

IN Pharmaceuticals

-0.6%

IN Market


1 Year Return

56.9%

GLENMARK

45.4%

IN Pharmaceuticals

0.9%

IN Market

Return vs Industry: GLENMARK exceeded the Indian Pharmaceuticals industry which returned 45.4% over the past year.

Return vs Market: GLENMARK exceeded the Indian Market which returned 0.9% over the past year.


Shareholder returns

GLENMARKIndustryMarket
7 Day0.6%-1.7%-0.6%
30 Day0.5%-0.8%4.0%
90 Day14.4%11.7%5.7%
1 Year57.7%56.9%47.2%45.4%2.6%0.9%
3 Year-20.4%-21.5%22.6%19.3%-2.8%-7.4%
5 Year-49.5%-50.5%-0.2%-3.7%39.9%29.5%

Price Volatility Vs. Market

How volatile is Glenmark Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Glenmark Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

14.87x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: GLENMARK (₹485.2) is trading above our estimate of fair value (₹276.32)

Significantly Below Fair Value: GLENMARK is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: GLENMARK is good value based on its PE Ratio (14.9x) compared to the IN Pharmaceuticals industry average (22.8x).

PE vs Market: GLENMARK is good value based on its PE Ratio (14.9x) compared to the Indian market (16.2x).


Price to Earnings Growth Ratio

PEG Ratio: GLENMARK is poor value based on its PEG Ratio (2.1x)


Price to Book Ratio

PB vs Industry: GLENMARK's PB Ratio (2.3x) is in line with the IN Pharmaceuticals industry average.


Next Steps

Future Growth

How is Glenmark Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?

7.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GLENMARK's forecast earnings growth (7.1% per year) is below the savings rate (7.2%).

Earnings vs Market: GLENMARK's earnings (7.1% per year) are forecast to grow slower than the Indian market (25.6% per year).

High Growth Earnings: GLENMARK's earnings are forecast to grow, but not significantly.

Revenue vs Market: GLENMARK's revenue (8.3% per year) is forecast to grow slower than the Indian market (11.3% per year).

High Growth Revenue: GLENMARK's revenue (8.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GLENMARK's Return on Equity is forecast to be low in 3 years time (13%).


Next Steps

Past Performance

How has Glenmark Pharmaceuticals performed over the past 5 years?

4.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GLENMARK has high quality earnings.

Growing Profit Margin: GLENMARK's current net profit margins (8.6%) are higher than last year (7.6%).


Past Earnings Growth Analysis

Earnings Trend: GLENMARK's earnings have grown by 4.6% per year over the past 5 years.

Accelerating Growth: GLENMARK's earnings growth over the past year (20.1%) exceeds its 5-year average (4.6% per year).

Earnings vs Industry: GLENMARK earnings growth over the past year (20.1%) exceeded the Pharmaceuticals industry 14.7%.


Return on Equity

High ROE: GLENMARK's Return on Equity (15.2%) is considered low.


Next Steps

Financial Health

How is Glenmark Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: GLENMARK's short term assets (₹68.0B) exceed its short term liabilities (₹41.3B).

Long Term Liabilities: GLENMARK's short term assets (₹68.0B) exceed its long term liabilities (₹44.9B).


Debt to Equity History and Analysis

Debt Level: GLENMARK's debt to equity ratio (68.7%) is considered high.

Reducing Debt: GLENMARK's debt to equity ratio has reduced from 125.3% to 68.7% over the past 5 years.

Debt Coverage: GLENMARK's debt is well covered by operating cash flow (33.4%).

Interest Coverage: GLENMARK's interest payments on its debt are well covered by EBIT (3.7x coverage).


Balance Sheet


Next Steps

Dividend

What is Glenmark Pharmaceuticals's current dividend yield, its reliability and sustainability?

0.52%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: GLENMARK's dividend (0.52%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.56%).

High Dividend: GLENMARK's dividend (0.52%) is low compared to the top 25% of dividend payers in the Indian market (2.29%).


Stability and Growth of Payments

Stable Dividend: GLENMARK's dividends per share have been stable in the past 10 years.

Growing Dividend: GLENMARK's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (7.7%), GLENMARK's dividend payments are thoroughly covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: GLENMARK's dividends in 3 years are forecast to be thoroughly covered by earnings (7% payout ratio).


Next Steps

  • Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Glenn Saldanha (50 yo)

19.75yrs

Tenure

₹122,350,000

Compensation

Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Limited since 2000. Mr. Saldanha serves as the Chief Executive Officer of Glenmark Pharmaceut ...


CEO Compensation Analysis

Compensation vs Market: Glenn's total compensation ($USD1.65M) is above average for companies of similar size in the Indian market ($USD598.71K).

Compensation vs Earnings: Glenn's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Glenn Saldanha
Chairman19.75yrs₹122.35m0.34%
₹ 456.4m
V. Mani
Global CFO & Executive Director2.42yrs₹51.50m0.00021%
₹ 283.1k
Harish Kuber
Company Secretary & Compliance Officer3.67yrs₹3.96mno data
Cherylann Pinto
Executive Director of Corporate Services & Executive Director21yrs₹45.21m0.27%
₹ 361.5m
Darshan Makhey
President & Chief Quality Officerno datano datano data
Jayaram Philkana
President & Global Chief Human Resources Officerno datano datano data
Sriram Venkatasubramanian
President & Head of Global Operations and Supply Chain0.83yrno datano data
Meera Vanjari
Senior VP of Legal & General Counselno datano datano data
Udaykumar Murthy
Senior Manager of Corporate Communicationsno datano datano data
P. Reddy
Executive Vice President and Global Head Business Developmentno datano datano data
T. Grover
Senior Vice President of Corporate Relationsno datano datano data
Michael Buschle
Chief Scientific Mentor4yrsno datano data

3.7yrs

Average Tenure

53yo

Average Age

Experienced Management: GLENMARK's management team is considered experienced (3.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Glenn Saldanha
Chairman19.75yrs₹122.35m0.34%
₹ 456.4m
V. Mani
Global CFO & Executive Director2.42yrs₹51.50m0.00021%
₹ 283.1k
Cherylann Pinto
Executive Director of Corporate Services & Executive Director21yrs₹45.21m0.27%
₹ 361.5m
Milind Sarwate
Independent Non-Executive Director5yrs₹1.80mno data
Brian Tempest
Independent Non-Executive Director8.75yrs₹400.00kno data
Blanche Saldanha
Non Executive Director15.17yrs₹400.00k0.39%
₹ 530.5m
Sridhar Gorthi
Independent Non-Executive Director15.5yrs₹400.00k0.00020%
₹ 269.6k
Rajesh Desai
Independent Director18.42yrs₹1.60m0.039%
₹ 52.2m
Devendra Mehta
Independent Non-Executive Director11.17yrs₹1.60mno data
Dipankar Bhattacharjee
Independent Non-Executive Director0.17yrno datano data
Bernard Munos
Independent Non-Executive Director8.75yrs₹400.00kno data
Sona Ramasastry
Independent Non-Executive Director1.5yrs₹400.00kno data

9.1yrs

Average Tenure

60yo

Average Age

Experienced Board: GLENMARK's board of directors are considered experienced (9.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: GLENMARK insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Glenmark Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Glenmark Pharmaceuticals Limited
  • Ticker: GLENMARK
  • Exchange: NSEI
  • Founded: 1977
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹134.820b
  • Shares outstanding: 282.17m
  • Website: https://www.glenmarkpharma.com

Number of Employees


Location

  • Glenmark Pharmaceuticals Limited
  • Glenmark House
  • B.D. Sawant Marg
  • Mumbai
  • Maharashtra
  • 400099
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
532296BSE (Mumbai Stock Exchange)YesEquity SharesININRFeb 2000
GLENMARKNSEI (National Stock Exchange of India)YesEquity SharesININRFeb 2000

Biography

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The compan ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/27 12:36
End of Day Share Price2020/10/27 00:00
Earnings2020/06/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.